The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US Distribution Agreement with ICU Medical

16 May 2016 07:00

RNS Number : 2634Y
LiDCO Group Plc
16 May 2016
 

 

16 May 2016 

LIDCO GROUP PLC

("LiDCO" or the "Company" or "the Group")

 

 US distribution agreement with ICU Medical

 

LiDCO (AIM: LID), the hemodynamic monitoring company, announces it has signed a distribution agreement with its partner ICU Medical, Inc. (NASDAQ: ICUI) to sell the LiDCO IM non-invasive hemodynamic monitoring system in the United States. LiDCO IM is a specially configured hemodynamic monitor produced exclusively for ICU Medical that works solely in conjunction with LiDCO's non-invasive module.

 

LiDCO and ICU Medical have an existing royalty agreement allowing ICU Medical to incorporate LiDCO's technology into its FDA 510(k)-cleared CogentTM 2-in-1 hemodynamic system, which combines both invasive and minimally invasive hemodynamic monitoring capability on a single platform. Both the Cogent in minimally invasive mode and the LiDCO IM non-invasive monitor use the LiDCO PulseCOTM algorithm to determine cardiac output and stroke volume, allowing continuity of measurement across patient acuity levels. ICU Medical announced on its Q1 2016 earnings call that the company plans further refinements of the Cogent system in advance of a full market release. Availability of the noninvasive LiDCO IM system is anticipated for Q3 2016.

 

Matt Sassone, CEO of LiDCO, commented: "The USA is the largest and fastest growing market for hemodynamic monitoring and our collaboration with ICU Medical is an important element of expanding our presence there. ICU Medical recognises the importance of being able to offer customers a suite of hemodynamic technologies incorporating LiDCO's technology, so we are pleased to announce this extension to our business relationship."

 

 

LiDCO Group Plc

www.lidco.com

Matt Sassone (CEO)

Tel: +44 (0)20 7749 1500

Paul Clifford (Finance Director)

finnCap

Tel: +44 (0)20 7600 1658

Geoff Nash / Emily Watts (Corporate Finance)

Stephen Norcross (Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or lidco@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

 

Key Products:

 

LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.

 

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

 

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

 

· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

 

The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 

 

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

 

*BISTM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAPTM is a trademark of CNSystems Medizintechnik AG.

 

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

 

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

 

LiDCO's headquarters are in London and its shares are traded on AIM.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMGMKKFZGVZM
Date   Source Headline
26th Jan 20064:38 pmPRNConvertible loan update
19th Jan 20067:00 amRNSProduct Development
19th Dec 20051:15 pmPRNResignation of a Director
8th Dec 20059:02 amPRNDirector Shareholding
18th Nov 20057:00 amRNSConversion of Loan
8th Nov 20057:01 amRNSPositive Study Data
3rd Nov 20057:00 amRNSUS Army Order
25th Oct 20057:01 amRNSClinical Advisory Board
18th Oct 20057:01 amRNSInterim Results
14th Oct 20051:39 pmPRNDirectorate Change
26th Sep 20059:11 amRNSNotice of Results
11th Aug 20057:02 amRNSUSD 2 Million Financing
14th Jul 20057:00 amRNSAdditional Listing
7th Jul 20057:01 amRNSNew Veterinary Application
23rd Jun 20054:00 pmRNSImpact of Review Paper
17th Jun 20057:00 amRNSBoard Appointment
16th Jun 20052:57 pmRNSAGM Statement
6th Jun 20052:38 pmPRNDirector Shareholding
1st Jun 20057:00 amRNSPositive Data
10th May 20052:20 pmPRNDirector Shareholding
9th May 20057:00 amRNSRegistration in Brazil
25th Apr 20057:00 amRNSAppointment of New Director
15th Apr 200511:46 amRNSDirector Shareholding
13th Apr 20057:00 amRNSDirector Share Options Award
7th Apr 20057:00 amRNSDirector Shareholding
30th Mar 20057:01 amRNSPreliminary Results
30th Mar 20057:01 amRNSProduct Approval in Denmark
24th Mar 20057:02 amRNSLaunch Of Software Upgrade
23rd Mar 200510:50 amPRNAdditional Listing
21st Mar 20057:02 amRNSSignificant Trial Results
15th Mar 20057:02 amRNSEuropean Approval
2nd Mar 20058:19 amRNSChange of Financial PR Agency
14th Feb 20057:00 amPRNMajor Clinical Trial
24th Jan 20053:25 pmPRNAdditional Listing
19th Jan 20054:16 pmPRNDirectorate Change
13th Jan 200511:28 amPRNAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.